BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  US Device


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


Eisai Inc. 

900 Davis Drive
P.O. Box 14505
Research Triangle Park  North Carolina  27709  U.S.A.
Phone: 919-941-6920 Fax: 919-941-6931


Headquartered in Woodcliff Lake, New Jersey, Eisai Inc. was established in 1995 and is ranked among the top-20 U.S. pharmaceutical companies (based on retail sales). The company began marketing its first product in the United States in 1997 and has rapidly grown to become a fully integrated pharmaceutical business. Eisai’s areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.

Eisai has a global product creation organization that includes U.S.-based R&D facilities in Maryland, Massachusetts, New Jersey, North Carolina and Pennsylvania as well as manufacturing facilities in Maryland and North Carolina. The company’s areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs. For more information about Eisai, please visit

 Key Statistics

Ownership: Subsidiary

Web Site: Eisai Inc.
Employees: 2600
Symbol: ESALF.PK


 Company News
Eisai Inc. (ESALF.PK) Launches National Television Advertising Campaign For BELVIQ® (lorcaserin HCl) CIV 4/14/2014 8:05:37 AM    More...
Otsuka Pharmaceutical Co., Ltd. Acquires Rights To Hematological Cancer Treatment Dacogen® From Eisai Inc. (ESALF.PK) (U.S.) 3/31/2014 8:21:36 AM    More...
Eisai Inc. (ESALF.PK)'s President And CEO To Retire 3/10/2014 7:34:24 AM    More...
Eisai Inc. (ESALF.PK) Announces Initiation Of A Phase 3 Trial Of Eribulin Mesylate Injection Versus Weekly Paclitaxel In First And Second Lines Of Metastatic Breast Cancer 2/27/2014 10:17:47 AM    More...
Eisai Inc. (ESALF.PK) Reports Improved Patient Access For BELVIQ® (lorcaserin HCI) CIV 2/10/2014 10:19:28 AM    More...
Eisai Inc. (ESALF.PK) Announces U.S. Availability Of FYCOMPA™ (Perampanel) CIII An Adjunctive Treatment For Partial-Onset Seizures In Patients With Epilepsy Age 12 And Older 1/2/2014 8:49:13 AM    More...
Eisai Inc. (ESALF.PK) Presents New Data Analyses on FYCOMPA™ (perampanel) at American Epilepsy Society Annual Meeting 12/5/2013 6:28:35 AM    More...
Eisai Company, Ltd. (ESALY.PK) Joins Groundbreaking Tuberculosis Drug Accelerator Partnership To Discover New Tuberculosis Drugs 11/26/2013 9:05:27 AM    More...
Eisai Inc. (ESALF.PK) Announces Partnership With NewBridge Pharmaceuticals To Market Breast Cancer Treatment Halaven® (Eribulin) Across The Middle East 11/18/2013 9:13:09 AM    More...
Eisai Inc. (ESALF.PK) Announces Availability of ACIPHEX® Sprinkle™ (Rabeprazole Sodium) for Treatment of GERD in Children Ages 1 to 11 11/8/2013 10:08:01 AM    More...